Probiotic Composition for Obesity Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-obesity medications are ineffective in the long term and cause significant side effects, while existing probiotic treatments for obesity and obesity-related disorders do not consistently demonstrate substantial weight loss or fat reduction.
Innovation Solution
A probiotic composition comprising Lactobacillus salivarius subsp. salicinius AP-32 and Bifidobacterium longum subsp. longum OLP-01, which are administered to inhibit fatty acid absorption and reduce body fat formation, offering synergistic efficacy in treating obesity and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional anti-obesity medications (sibutramine, orlistat) are used to suppress appetite or inhibit fat absorption, then weight loss effect is achieved, but serious side effects and adverse effects occur
Solution Approach 1:
The patent changes the fundamental parameter of the treatment approach from pharmacological intervention to probiotic intervention. By using specific strains of Lactobacillus and Bifidobacterium, the treatment achieves weight loss through biological modulation of the gut microbiota rather than direct pharmacological action on appetite or fat absorption, thereby avoiding the side effects associated with conventional medications.
Solution Approach 2:
The patent employs probiotic bacteria that are naturally occurring, safe, and can be administered as live biological agents. These probiotics work temporarily to modulate gut function and can be replenished regularly, providing a safer alternative to long-term pharmacological treatment that accumulates in the body and causes persistent side effects.
2Quantity of substance
If existing probiotic treatments are used for obesity, then some reduction in energy intake is achieved, but no significant improvement in waist circumference and body mass occurs
Solution Approach 1:
The patent combines two specific probiotic strains (Lactobacillus salivarius and Bifidobacterium longum) in a synergistic formulation. This combination approach merges the benefits of different bacterial species to achieve both energy intake reduction and significant body mass reduction, overcoming the limitation of single-strain or existing multi-strain probiotics that only partially addressed the problem.
Solution Approach 2:
The patent creates a composite probiotic formulation containing specific ratios of different bacterial strains. This composite approach allows the probiotics to work synergistically, with each strain contributing different metabolic functions that collectively produce significant weight loss and body mass reduction effects that neither strain could achieve alone.
3Duration of action of stationary object
If long-term use of anti-obesity drugs is continued, then appetite suppression or fat absorption inhibition is maintained, but the desired weight loss effect is not achieved and side effects accumulate
Solution Approach 1:
The probiotic formulation works by colonizing the gut and establishing a self-sustaining beneficial microbial community. Once established, these probiotics continue to modulate metabolism, improve insulin sensitivity, and regulate appetite through natural biological mechanisms, eliminating the need for continuous external pharmacological intervention and avoiding the diminishing returns and side effect accumulation seen with long-term drug use.
Data Source
AI summary
Disclosed herein is a probiotic composition including Lactobacillus salivarius subsp. salicinius AP-32 that is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and Bifidobacterium longum subsp. longum OLP-01 that is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 17345. Also disclosed herein are use of at least one of the abovementioned lactic acid bacterial strains for treating obesity and/or an obesity-related disorder, and for inhibiting fat absorption.